GlassScriptPhysician profile
Rodhan A Khthir
NPI 1164852646
$1,729.85
in general payments reported to CMS, 2019-2025
24 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2021: $57.21 · 2022: $46.20 · 2023: $315 · 2024: $472 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $191.33 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $180.65 | 2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $167.52 | 2022-2024 | |
| Amgen INC. | $158.79 | 2023-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $145.67 | 2024-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $120.34 | 2019-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.09 | 2019-2025 | Ofev, Jardiance |
| Nevro Corp. | $99.27 | 2023 | Senza |
| Insulet Corporation | $81.18 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $77.78 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $55.39 | 2023-2024 | Strensiq |
| Chiesi USA, INC. | $49.86 | 2024-2025 | Mycapssa |
| Astellas Pharma US INC | $40.65 | 2024-2025 | Veozah |
| Boston Scientific Corporation | $38.67 | 2024 | |
| Lilly USA, LLC | $32.24 | 2021-2025 | Mounjaro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $28.54 | 2025 | Hyrimoz |
| Radius Health, INC. | $27.28 | 2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $25.39 | 2025 | Acthar |
| Xeris Pharmaceuticals, INC. | $24.37 | 2021 | |
| Medtronic Minimed, INC. | $18.96 | 2019 | |
| Eisai INC. | $16.53 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $15.52 | 2022 | |
| Tandem Diabetes Care, INC. | $14.25 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodhan Khthir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.